Bio-Rad reports Q1 EPS $2.29, consensus $2.15

Reports Q1 revenue $610.8M, consensus $619.09M. The company said, “Our first quarter results were largely in line with expectations. The ongoing weakness in the biotech and biopharma markets impacted sales of our life science research products while increased demand for our clinical diagnostics products drove year-over-year growth for this business. We are cautiously optimistic about a gradual biopharma market recovery in the second half of the year and remain confident in our overall strategy and long-term market opportunities.”